Introduction
► Product development success is measured not only in terms of achieving regulatory approval but also in terms of achieving timely market access for the indicated patient population at the target price. ► Achieving timely market access requires delivering a compelling value proposition with substantiated incremental benefit to address unmet needs at launch. The objective of the present study was to illustrate, using the example of pain, how identifying the relationships between health states utilities can support or refute hypotheses, optimize indication selection and sequencing and inform the definition of clinical trial inclusion criteria in early development.
Methods
Data Source ► Data from the 2011 U.S. National Health and Wellness Survey (NHWS) were used. The NHWS is a large (N=75,000), population-level, health survey conducted through the Internet each year. ► Respondents of the NHWS are recruited from an Internet panel using a random stratified sampling framework to ensure consistency with the U.S. Census with respect to demographic distributions. Sample ► Of the 75,000 respondents who completed the 2011 U.S. NHWS, only patients who reported that they had experienced pain in the past month were included in the analyses.
Measures
► Sociodemographics. Age, sex, ethnicity, marital status, and education were also assessed. ► Health History. The body mass index and Charlson comorbidity index were calculated for each respondent. ■ BMI was calculated from patient self-reported height and weight. The BMI for those who did not self-report was set to missing. ■ The Charlson comorbidity index (CCI) was also used to provide a summary index of overall comorbidity burden; this index weights comorbidities based on their relationships with future mortality (e.g., metastatic cancer is weighted more heavily than rheumatoid arthritis) and then summed together. ■ Individual comorbidities were also listed to highlight specific conditions prevalent among those with pain. ► Pain History. Type of pain (which was used to classify respondents into neuropathic or nociceptive pain) and a pain severity rating in the last week (from 0 to 10) were also included. ► Health Status. The survey assesses patient health status utilizing the Short Form 12 version 2 (SF-12v2) and health utilities were calculated using the SF-6D algorithm.
Analyses
Characterizing Those with Pain ► Descriptive analyses were conducted to characterize those who experienced pain in the past month. Modeling the Relationship between Pain Severity and Health Utilities ► Descriptive analyses were conducted to characterize the distribution of health utilities. ► General linear models were then examined to predict health utilities from pain severity, holding age, gender, ethnicity, education, and the CCI constant. The primary hypothesis was that there was a linear relationship between pain severity and health utilities, though other functional forms (e.g., quadratic, cubic) were examined post-hoc. Investigating Subgroups ► As an example of investigating subgroups, a selection of the above analyses (with emphasis on the modeling of the pain severity-to-health utilities association) were conducted among those with neuropathic pain and among those with nociceptive pain.
Abstract
Objectives: The aim of this project was to provide an example of how mapping the relationship between clinical states and health utilities can inform early development strategy and clinical trial inclusion criteria with the intention of optimizing benefit substantiation. The ability to substantiate incremental benefit is critical for achieving market access for the indicated patient population. Methods: US 2011 National Health and Wellness Survey data were used. Respondents with pain in the past month were included. Patient characteristics were summarized and general linear models were used to examine the relationship between pain severity in the last week (0 to 10 scale) and health utilities while controlling for sociodemographics and health history. Models were replicated within pain subgroups (e.g., neuropathic pain, nocioceptive pain etc). Results: 24,778 respondents (33.04%) reported pain in the past month (mean age = 50.24; 51.71% were female). The range of health utilities (as determined by the SF-6D algorithm) was 0.35-1.00. Pain severity was significantly negatively associated with health utilities (b=-0.025, p<0.05), though a cubic relationship was also identified whereby a 1-point reduction in pain was associated with a greater increase in utilities among those with mild pain (e.g., a reduction from 1 to 0 on the pain scale led to 0.027 increase in utilities) compared with those with severe pain (reduction from 10 to 9 lead to 0.010 increase in utilities). Subgroups were also investigated to understand variations by potential indication or inclusion criteria. For example, only a significant linear relationship (no higher order trends) between pain severity and health utilities was observed among those with neuropathic pain (b=-0.27, p<0.05).
Conclusions:
The overall relationship between pain severity and health utilities was non-linear suggesting that more incremental value could be substantiated by reducing milder pain than more severe pain. However, not all subgroups followed this pattern emphasizing the benefits of understanding the relationship between estimated treatment effects and health utilities early in the developmental process. This approach to establish whether value can be substantiated as hypothesized and how indication and patient selection may affect the ability to demonstrate incremental benefit.
Results
Characterizing Those with Pain ► 24,778 respondents (33.04%) reported pain in the past month (mean age = 50.24; 51.71% were female; see Table 1 ). Respondents with pain were more likely to be non-Hispanic white and obese than respondents without pain. ► The ten most prevalent comorbidities are displayed in Figure 1 , highlighting conditions which may complicate disease management or may very well be the cause of the current pain. The comorbidity profile differed within subgroups, however. Patients with moderate-to-severe pain reported levels of osteoarthritis (32.74%), sleep difficulties (35.00%), and depression (31.60%) that were 30% higher than the general pain population. Modeling the Relationship between Pain Severity and Health Utilities ► The broad range of health utilities (0.35-1.00, Mean = 0.69, SD=0.14) suggests that there is sufficient variability to, in theory, be affected by a treatment intervention (see Figure 2 ). Of course, few patients have very low health utilities suggesting that improvement in this domain because of treatment intervention will most often be for those with a baseline health utility in the 0.60 to 0.70 range.
Conclusions
► These results provide an example of how hypothesis testing can help to inform early development strategy for a pain compound. ► As the comorbidity profile shifts distinctly across various subgroups within pain, a thorough analysis of how these comorbidities influence the existing unmet needs and the potential for demonstrating a response in patients can inform inclusion/exclusion criteria for future clinical trials. ► These results also suggest that the relationship between efficacy/effectiveness and domains such as health utilities may not be a linear one. Depending upon the baseline level, the same patient response may have a different influence on health utilities and, subsequently, impact the cost effectiveness calculations. ► Of particular importance is how all of the above analyses varied substantially across subgroups (e.g., overall pain, moderate-to-severe, neuropathic pain). ► In sum, these results suggest that analyses early in development can help identify the indication and patient population with the best chance of showing incremental benefit substantial enough to demonstrate value and compel funding. ► Although a linear relationship was observed as hypothesized, such that pain severity was significantly negatively associated with health utilities controlling for confounders (b=-0.025, p<0.05), post-hoc analyses revealed a significant cubic relationship. Specifically, a 1-point reduction in pain severity was associated with a greater increase in utilities among those with mild pain (e.g., a reduction from 1 to 0 on the pain scale led to 0.027 increase in utilities) compared with those with severe pain (reduction from 10 to 9 lead to 0.010 increase in utilities; see Figure 3 ). Investigating Subgroups ► Interestingly, this pattern was not consistent across subgroups. A cubic relationship was observed for patients with nociceptive pain but only a significant linear relationship (no higher order trends) was observed for patients with neuropathic pain (b=-0.027, p<0.05). For patients with neuropathic pain, a 1-point reduction in pain severity was just as beneficial for those patients regardless where their level of pain severity was at baseline (see Figure 3) . 
